News | May 11, 2023
Orchid Pharma Q4 FY23 consolidated PAT up at Rs. 59.13 Cr
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 125.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1407.34 crores during the period ended March 31, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Subscribe To Our Newsletter & Stay Updated
